// App-Quantinova.ai

4501 : CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Camillo Porta

  • Nicola Jane Lawrence

  • Robert J. Motzer

  • Richard J. Lee

  • Rohit K. Jain

  • Nancy B. Davis

  • Leonard Joseph Appleman

  • Oscar B. Goodman

  • Walter Michael Stadler

  • Sunil G. Gandhi

  • Daniel M. Geynisman

  • Roberto Iacovelli

  • Begona Mellado

  • Robert A. Figlin

  • Thomas Powles

  • Lalith V Akella

  • Keith W. Orford

  • Bernard Escudier

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, University of Bari 'A. Moro' and Policlinico Consorziale di Bari, Bari, Italy

  • Auckland City Hospital, Auckland, New Zealand

  • Memorial Sloan Kettering Cancer Center, New York, NY, Massachusetts General Hospital Cancer Center, Boston, MA

  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Vanderbilt-Ingram Cancer Center, Nashville, TN, University of Pittsburgh Medical Center, Pittsburgh, PA, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, The University of Chicago, Chicago, IL

  • Florida Cancer Specialists, Lecanto, FL, Fox Chase Cancer Center, Department of Hematology and Oncology, Philadelphia, PA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

  • St Bartholomews Hospital, Barts Health NHS Trust, , United Kingdom

  • Calithera Biosciences Inc, South San Francisco, CA

  • Gustave Roussy, Villejuif, France

Locations

  • Italy

  • New Zealand

  • Spain

  • United Kingdom

  • France

Companies

  • Calithera Bioscience

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

  • CB-839

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • N/A

Study Id's

  • NCT03428217

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved